Purpose of the development: Designed for outdoor treatment of inflammatory processes (septic wounds, including post-operative, osteitis, osteomyelitis, venous ulcers, the treatment of acute superficial and deep burns in the last eoperatsionnom period - after dermal sculpture, etc.).

Recommended application field: Ministry of Health

Technical characteristic: Izofural - a completely new product, developed on the basis of new chemical compounds of nitrofurans. Registered since: Beta SRL Izofural, 0.05% solution, 30 ml. Registration Nr 16886 on 05/10/2011 Izofural, 0.05% solution, 250 ml. Registration Nr 16886 on 05/10/2011

Advantages over analogues: The drug is 12 times less toxic, and 5-20 times more active (depending on the type of microorganism) as compared with the structural analogue - furatsilinom

The development stage readiness: Ready for application

Description of the development:
()
Antiseptic. Nitrofuran derivative. Transparent viscous liquid bone, yellow, and odorless. Bactericidal effect against gram-positive and gram-negative microorganisms as soon as possible after contact with them (the first 2-5 hours). It is well absorbed into the skin to form on its surface a protective film. Accelerates tissue regeneration, and promotes rapid healing of wounds. It has a softening effect.

corresponds technical description
Ready for implementation

Possibility of transfer abroad:
Licence's sale
Combinated reduction to industrial level

Photo

Country Moldova

For additional information turn to:
E-mail: gal@uintei.kiev.ua